Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
Novartis
AstraZeneca
Ipsen
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Palleos Healthcare GmbH
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Gilead Sciences
Corcept Therapeutics
Merck Sharp & Dohme LLC
NGM Biopharmaceuticals, Inc
Precision Biologics, Inc
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Immodulon Therapeutics Ltd
Kyntra Bio
US Oncology Research
Merck Sharp & Dohme LLC
Celgene
Bristol-Myers Squibb
EQRx International, Inc.
Processa Pharmaceuticals
Corcept Therapeutics
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Celgene
Nektar Therapeutics
Kyntra Bio
Mereo BioPharma
Corcept Therapeutics
Merck Sharp & Dohme LLC
ERYtech Pharma
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Eli Lilly and Company
Mereo BioPharma
Celgene
Halozyme Therapeutics
Halozyme Therapeutics
Celgene
Incyte Corporation
Celgene
Celgene
Celgene
Celgene
Celgene